(S (NP (JJ Modern) (NN medicine)) (VP (VBZ requires) (NP (NP (JJ generalised) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN synthesis) (CC and) (NN integration)) (PP (IN of) (NP (NP (NN multimodal) (NNS data)) (, ,) (PP (ADVP (RB often)) (IN at) (NP (JJ different) (JJ biological) (NNS scales))) (, ,))))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN applied) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NN evidence) (NNS structures)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ complex) (NN disease) (NNS analyses)) (CC and) (NP (JJ epidemiological) (NNS models))))))))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (JJ current) (NNS methods)) (VP (VBP are) (UCP (ADJP (DT either) (ADJP (JJ slow) (CC and) (JJ expensive)) (, ,) (CC or) (ADJP (JJ ineffective))) (PP (JJ due) (TO to) (NP (DT the) (NN inability) (S (VP (TO to) (VP (VB model) (NP (NP (DT the) (JJ complex) (NNS relationships)) (PP (IN between) (NP (NP (NNS data) (NNS modes)) (SBAR (WHNP (WDT which)) (S (VP (VBP differ) (PP (IN in) (NP (NN scale) (CC and) (NN format)))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP address) (NP (DT these) (NNS issues)) (PP (IN by) (S (VP (VBG proposing) (NP (NP (DT a) (JJ cross-modal) (NX (NX (JJ deep) (NN learning) (NN architecture)) (CC and) (NX (NN co-attention) (NN mechanism)))) (SBAR (S (VP (TO to) (VP (ADVP (RB accurately)) (VB model) (NP (NP (DT the) (NNS relationships)) (PP (IN between) (NP (DT the) (JJ different) (NNS data) (NNS modes)))) (, ,) (SBAR (IN while) (S (VP (ADVP (JJ further)) (VBG reducing) (NP (JJ patient) (NN diagnosis) (NN time)))))))))))))) (. .))
(S (S (VP (VBG Differentiating) (NP (NP (NNP Parkinson) (POS 's)) (NNP Disease) (PRN (-LRB- -LRB-) (NP (NNP PD)) (-RRB- -RRB-)) (NNS patients)) (PP (IN from) (NP (JJ healthy) (NNS patients))))) (VP (VBZ forms) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (DT the) (NN evaluation))))) (. .))
(S (NP (DT The) (NN model)) (VP (VBZ outperforms) (NP (DT the) (JJ previous) (JJ state-of-the-art) (JJ unimodal) (NN analysis)) (PP (IN by) (NP (CD 2.35) (NN %))) (, ,) (SBAR (IN while) (S (ADVP (RB also)) (VP (VBG being) (ADJP (ADJP (NP (CD 53) (NN %)) (JJR more) (NN parameter) (NN efficient)) (PP (IN than) (NP (DT the) (NN industry) (VBD standard) (JJ cross-modal) (NN model)))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (DT the) (NN attention) (NNS coefficients)))) (VP (VBZ allows) (SBAR (IN for) (S (NP (JJ qualitative) (NNS insights)) (VP (TO to) (VP (VB be) (VP (VBN obtained))))))) (. .))
(S (PP (IN Through) (NP (NP (DT the) (NN coupling)) (PP (IN with) (NP (NNS bioinformatics))))) (, ,) (NP (NP (DT a) (JJ novel) (NN link)) (PP (IN between) (NP (NP (DT the) (JJ interferon-gamma-mediated) (NN pathway)) (, ,) (NP (NNP DNA) (NN methylation)) (CC and) (NP (NNP PD))))) (VP (VBD was) (VP (VBN identified))) (. .))
(S (NP (PRP We)) (VP (VBP believe) (SBAR (IN that) (S (NP (PRP$ our) (NN approach)) (VP (VP (VBZ is) (ADJP (JJ general))) (CC and) (VP (MD could) (VP (VB optimise) (NP (NP (DT the) (NN process)) (PP (IN of) (NP (NP (JJ medical) (NN evidence) (NN synthesis)) (CC and) (NP (NN decision) (NN making))))) (PP (IN in) (NP (DT an) (JJ actionable) (NN way))))))))) (. .))
